EFFECTS OF PHOTOHEMOTHERAPY ON THE CLINICAL COURSE OF BRONCHIAL ASTHMA

Cover Page


Cite item

Full Text

Abstract

Background: Anti-inflammatory and immunoregulatory effects of photohemotherapy have been demonstrated in myocarditis, chronic obstructive pulmonary disease, some autoimmune and other disorders. There are only limited reports on the use of photohemotherapy in bronchial asthma (BA). Aim: To assess the influence of blue- and red-light photohemotherapy on clinical course of BA. Materials and methods: 480 hospitalized patients with persistent moderate BA and mild (44.5%) or moderate (55.5%) exacerbation were randomized to receive standard therapy of asthma exacerbation and photohemotherapy (treatment group, n=250) or standard therapy only (control group, n=230). Blue-light photohemotherapy (photodiode apparatus Solaris, n=220) or redlight photohemotherapy (helium-neon gas laser, n=30) was applied according to the schedule: procedure duration – 30 minutes, number of sessions – 5–7, every 2–3 days. Results: In asthma exacerbation, adding photohemotherapy to standard treatment was associated with more rapid improvement of clinical symptoms: maximal total asthma scores were achieved by the day 7–10 in patients with mild exacerbation and by the day 10–14 in patients with moderate exacerbation. Therapeutic effects of blue-light photohemotherapy were superior to those of red-light photohemotherapy. The data of 3-year follow-up supported the role of photohemotherapy in achieving asthma control: in the treatment group, proportion of patients with total control of asthma was 1.3-fold higher and one-year hospitalization number was lower by 34.8% compared with the controls. Conclusion: Blue-light and red-light photohemotherapy positively influences the clinical course of asthma and is associated with faster remission achievement and reduction of duration and frequency of hospitalizations.

About the authors

E. I. Ostrovskiy

Moscow Regional Research and Clinical Institute (MONIKI); 61/2 Shchepkina ul., Moscow, 129110, Russian Federation

Author for correspondence.
Email: ostrovskyei@mail.ru
PhD, Head of the Internal Diseases Department No. Россия

V. I. Karandashov

State Research Center for Laser Medicine of the Federal Medical and Biological Agency of the Russian Federation; 40 Studencheskaya ul., Moscow, 121165, Russian Federation

Email: fake@neicon.ru
MD, PhD, Professor, Member of the Russian Academy of Natural Sciences; the Head of the Department for Laser Biotechnologies and Clinical Pharmacology Россия

S. N. Shatokhina

Moscow Regional Research and Clinical Institute (MONIKI); 61/2 Shchepkina ul., Moscow, 129110, Russian Federation

Email: fake@neicon.ru
PhD, the Head of the Clinical Diagnostic Laboratory Россия

N. P. Sanina

Moscow Regional Research and Clinical Institute (MONIKI); 61/2 Shchepkina ul., Moscow, 129110, Russian Federation

Email: fake@neicon.ru
MD, PhD, Professor, Internal Diseases Department, Postgraduate Medical School Россия

O. Yu. Ryzhkova

Moscow Regional Research and Clinical Institute (MONIKI); 61/2 Shchepkina ul., Moscow, 129110, Russian Federation

Email: fake@neicon.ru
polyclinic physician Россия

E. M. Katlomina

Moscow Regional Research and Clinical Institute (MONIKI); 61/2 Shchepkina ul., Moscow, 129110, Russian Federation

Email: fake@neicon.ru
Junior Research Fellow, Internal Diseases Department, Postgraduate Medical School Россия

N. R. Paleev

Moscow Regional Research and Clinical Institute (MONIKI); 61/2 Shchepkina ul., Moscow, 129110, Russian Federation

Email: fake@neicon.ru
Member of the Russian Academy of Sciences, MD, PhD, Professor, Chief of the Internal Diseases Department, Postgraduate Medical School Россия

References

  1. Палеев НР, ред. Болезни органов дыхания. Руководство для врачей. М.: Медицина; 2000. 726 с. (Paleev NR, editor. Diseases of the respiratory system. Physician Manual. Moscow: Meditsina; 2000. 726 p. Russian).
  2. Ишина ТИ, Кахновский ИМ, Макаpова ОВ, Соломатин АС, Алексеева МЕ. Изучение клинической эффективности внутpивенного лазеpного облучения кpови, плазмафеpеза и их сочетания у больных бpонхиальной астмой. Терапевтический архив. 2001;(3):15–9.(Ishina TI, Kakhnovskiy IM, Makapova OV, Solomatin AS, Alekseeva ME. [Clinical efficacy of intravenous laser, plasmapheresis and their combination in patients with bronchial asthma]. Terapevticheskiy arkhiv. 2001;(3):15–9. Russian).
  3. Newman LS. Occupational asthma. Diagnosis, management, and prevention. Clin Chest Med. 1995;16(4):621–36.
  4. Postma DS, Bleecker ER, Amelung PJ, Holroyd KJ, Xu J, Panhuysen CI, Meyers DA, Levitt RC. Genetic susceptibility to asthma – bronchial hyperresponsiveness coinherited with a major gene for atopy. N Engl J Med. 1995;333(14):894–900.
  5. Thompson S. On the social cost of asthma. Eur J Respir Dis Suppl. 1984;136:185–91.

Supplementary files

Supplementary Files
Action
1. JATS XML

Copyright (c) 2014 Ostrovskiy E.I., Karandashov V.I., Shatokhina S.N., Sanina N.P., Ryzhkova O.Y., Katlomina E.M., Paleev N.R.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies